IL5 and eosinophilic esophagitis: Indeed, several clinical studies have evaluated the biotherapeutic efficacy of monoclonal antibodies specifically targeting IL-4, IL-5, and IL-13 signals in both children and adolescents with EoE.77, –79 Results showed that targeting these downstream cytokines of IL-33 could significantly reduce the infiltration of eosinophils in the esophageal mucosa, alter histopathologic features, and improve clinical manifestations,77, –79 suggesting that EoE patients might benefit from these targeting therapeutic strategies.